At the recent EULAR meeting, a presentation by Nanjing Leads Biolabs Co. Ltd. covered the discovery of LBL-047, a novel bifunctional fusion protein targeting both plasmacytoid dendritic cells (pDCs) and B cells; it is being developed for the treatment of autoimmune diseases.
KYV-201 is an investigational allogeneic anti-CD19 CAR T-cell therapy candidate being developed by Kyverna Therapeutics Inc. for the treatment of B-cell-driven autoimmune diseases.
Vyrnwy Therapeutics Inc. has disclosed non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of autoimmune diseases.
As South Korea’s Curocell Inc. looks to develop the country’s first homegrown CAR T-cell therapy, CEO Gunsoo Kim highlighted rising and falling trends in the global CAR T development space at Bio Korea 2024.
Researchers from Fate Therapeutics Inc. presented preclinical data for the multiplexed-engineered, off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapy, FT-522, as a potential therapeutic against autoimmune diseases.
Aqilion AB has expanded its pipeline through the nomination of protein kinase C θ (PKCθ) as the target of a new immunology project. The PKCθ kinase is believed to be centrally involved in the pathogenesis of T-cell-mediated inflammatory and autoimmune diseases.
As South Korea’s Curocell Inc. looks to develop the country’s first homegrown CAR T-cell therapy, CEO Gunsoo Kim highlighted rising and falling trends in the global CAR T development space at Bio Korea 2024.
The bifunctional antibody approach continues to pay off for Zenas Biopharma Inc., which banked an upsized $200 million series C preferred stock financing led by SR One along with NEA, Norwest Venture Partners and Delos Capital. Enavate Sciences and Longitude Capital participated significantly as well.
Repertoire Immune Medicines Inc. has entered a multiyear strategic collaboration with Bristol Myers Squibb Co. (BMS) to develop tolerizing vaccines for up to three autoimmune diseases.
